Brenus Pharma

France - Lyon

• 19/09/2024
• Series A
• $25,000,000

Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC) designed to generate 'first-in-class', 'off-the-shelf' therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.

🧬STC mimics the relapse conditions of patients' tumor cells to educate their immune systems to be able to anticipate, target and destroy these tumor cells as soon as they appear and regardless of theur evolution.

Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer (mCRC), 2nd cause of cancer-related deaths wordlwide.

We are building a strong portfolio in solid tumors, leveraging our STC platform, to change a paradigm in oncology by making patients once again actors in their treatment.


🚀DARE TO INNOVATE 🚀

Related People

Paul BravettiFounder

France - ND

- Pharm. D with specialization in Oncology / Msc Marketing and Management HEC Paris
-15 years'​ experience in Pharmaceutical industry in Europe and Asia(Marketing and Medical senior positions)
-Strategic thinking and agility developed thanks to a multi-market Biotech and Large Pharma experience-
-Strong launch experience through 6 successful launches in Oncology and Cardiology (vemurafenib, brigatinib, TAK788, Triplixam,...)

LinkedIn https://www.linkedin.com/in/paul-bravetti/